Greenwich LifeSciences Raises Cash to $10.5M; Phase III Arm Shows 70–80% Recurrence Reduction
Greenwich LifeSciences sold shares via its ATM in Q1 2026 exceeding its cash burn, boosting its cash balance to approximately $10.5 million as of March 31, 2026. FLAMINGO-01’s non-HLA-A*02 arm is fully enrolled with 250 patients and shows a preliminary 70–80% reduction in breast cancer recurrence after primary immunization.
1. ATM Financing Boosts Cash Position
Greenwich LifeSciences utilized its at-the-market equity program to sell common stock directly into the market during Q1 2026, raising more than its cash burn for the quarter and ending March 31 with roughly $10.5 million in cash on hand. These unaudited figures provide funding runway to support ongoing clinical operations and the FLAMINGO-01 trial.
2. FLAMINGO-01 Enrollment Progress
The open-label Phase III trial has screened over 1,000 patients at an annual rate of about 800, and the 250-patient non-HLA-A*02 treatment arm is now fully enrolled. All patients in this arm received the primary immunization series of six injections over six months followed by booster doses every six months.
3. Preliminary Efficacy Trends
Early analysis of the non-HLA-A02 arm indicates a 70–80% reduction in recurrence rates after completing the primary immunization series, mirroring the hazard ratios observed in the Phase IIb HLA-A02 cohort, where GLSI-100 showed up to an 80% recurrence reduction over five years. Safety and immune response metrics are also tracking similarly to prior data, though results remain preliminary pending full data review.